对获批登革热疫苗的争议与辩论:不恰当亚组分析与选择性报告可能对大规模疫苗接种造成危害
本文针对登革热疫苗 Dengvaxia 的已发表 Meta 分析提出质疑,指出该分析在报告亚洲试验(CYD14)时仅强调<5岁儿童登革热住院风险升高七倍,却未指出严重登革热住院的另一危害信号;作者认为支持9岁及以上儿童安全的亚组分析因事后分析、未报告交互检验(P=0.14)及缺乏生物学依据而可信度有限。
要点
- 亚洲试验(CYD14)中<5岁儿童登革热住院风险升高七倍。
- 严重登革热住院:<9岁儿童相对危险度8.5(95%CI: 0.5, 146.8)。
- 总体研究组严重登革热住院相对危险度5.5(95%CI: 0.9, 33)。
核心结论
- 选择性报告和不恰当的亚组分析主张掩盖了登革热大规模疫苗接种项目的潜在危害。
研究设计与样本
- 本文为对一项已发表 Meta 分析(针对 Dengvaxia 疫苗安全性)的评论与辩论。
主要发现
- 亚洲试验(CYD14)中<5岁儿童登革热住院风险升高七倍。
- 严重登革热住院:<9岁儿童相对危险度8.5(95%CI: 0.5, 146.8),总体研究组相对危险度5.5(95%CI: 0.9, 33)。
- 支持9岁及以上儿童安全的亚组分析为事后分析、属于大量亚组分析之一,交互检验未报告但不显著(P=0.14),且无9岁阈值年龄的生物学依据。
- 作者认为年轻儿童风险更高更可能由ADE(更频繁的血清阴性)而非年龄本身解释。
关键数值与推荐
- 严重登革热住院在<9岁儿童中相对危险度8.5(95%CI: 0.5, 146.8)。
- 严重登革热住院在总体研究组中相对危险度5.5(95%CI: 0.9, 33)。
- 亚组分析交互检验P=0.14。
临床怎么用
- 计划公共使用该疫苗的国家必须进行严格的上市后监测。
- 必须获得潜在接种者父母的知情同意。
- 必须密切监测临床试验参与者正在进行的长期随访结果。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe life-threatening dengue fever usually occurs when a child is infected by dengue virus a second time. This is caused by a phenomenon called antibody-dependent enhancement (ADE). Since dengue vaccines can mimic a first infection in seronegative children (those with no previous infection), a natural infection later in life could lead to severe disease. The possibility that dengue vaccines can cause severe dengue through ADE has led to serious concern regarding the safety of mass vaccination programs. A published meta-analysis addressed this safety issue for a new vaccine against dengue fever-Dengvaxia. The trials in this meta-analysis have been used to campaign for mass vaccination programs in developing countries. We discuss the results of this paper and point out problems in the analyses. Reporting the findings in an Asian trial (CYD14), the authors show a sevenfold rise in one outcome-hospitalization for dengue fever in children <5 years old. However, they fail to point out two signals of harm for another outcome-hospitalization for severe dengue fever (as confirmed by an independent data monitoring committee): 1. In children younger than 9 years, the relative risk was 8.5 (95% confidence interval [CI]: 0.5, 146.8), and 2. In the overall study group, the relative risk was 5.5 (95% CI: 0.9, 33). The authors conduct a subgroup analysis to support claims that the vaccine is probably safe among children aged 9 years or more. This subgroup analysis has limited credibility because: (1) it was a post hoc analysis; (2) it was one of a large number of subgroup analyses; (3) the test of interaction was not reported, but was insignificant (P = 0.14); and (4) there is no biological basis for a threshold age of 9 years. The more likely explanation for the higher risk in younger children is ADE, that is, more frequent seronegativity, rather than age itself. The selective reporting and inappropriate subgroup claims mask the potential harm of dengue mass vaccination programs. Countries planning public use of the vaccine must conduct diligent postmarketing surveillance, secure informed consent from parents of potential recipients, and closely monitor the results of ongoing long-term follow-up of clinical trial participants.
引用
- Dans AL, Dans LF, Lansang MAD, et al. Controversy and debate on dengue vaccine series-paper 1: review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs. J Clin Epidemiol. 2017. PMID: 29180056. doi:10.1016/j.jclinepi.2017.11.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。